Linagliptin Catalog No.:M10654-10 InChi: InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4

InChi: InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4

Solubility: DMSO: 56 mg/mL(201

In the clone A replicon assay

InChiKey: PXZFKAKWSHBDCP-UHFFFAOYSA-N

InChiKey: ZCJHEORDHXCJNB-UHFFFAOYSA-N

Linagliptin Catalog No.:M10654-10 InChi: InChI=1S/C14H15ClN6O/c1-7-4-17-9(8(2)11(7)22-3)5-21-6-18-10-12(15)19-14(16)20-13(10)21/h4Linagliptin, also known as BI 1356, is a DPP 4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly. Product information CAS Number: 668270 12 0 Molecular Weight: 472. 54 Formula: C25H28N8O2 Chemical Name: 8 [(3R) 3 aminopiperidin 1 yl] 7 (but 2 yn 1 yl) 3 methyl 1 [(4